{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-23-000054","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.092184+00:00","generated_at":"2026-06-10T08:23:22.875384+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven reports >90% IgG reduction with BHV-1300 bispecific degrader after repeat dosing","bullets":["BHV-1300 bispecific IgG degrader achieved >90% reduction in IgG after repeat dosing in pharmacodynamic study.","The data was disclosed in a new corporate presentation dated September 27, 2023.","BHV-1300 targets elimination of pathogenic IgG for autoimmune disease therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-23-000054","json":"https://secwatch.observer/filing/0001935979-23-000054.json","markdown":"https://secwatch.observer/filing/0001935979-23-000054.md","text":"https://secwatch.observer/filing/0001935979-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000054/0001935979-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597923000054/bhvn-20230927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:23:22.875384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}